azd-3480
Small moleculeexperimental
Clinical trial activity
19 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00109564)
Timeline
Indications
Mechanism of action
- Neuronal acetylcholine receptor; alpha4/beta2PARTIAL AGONIST
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1- Mol. weight
- 234.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL188462 ↗
Also known as
- azd3480
- azd3480
- azd3480
- azd-3480
- azd-3480
- ispronicline
- ispronicline
- ispronicline
- ispronicline
- n-methyl-5-(3-(5-isopropoxypyridinyl))-4-penten-2-amine
- (s)-(e)-n-methyl-5-(3-(5-isopropoxypyridinyl))-4-penten-2-amine
- tc-01734
- tc-01734
- tc1734
- tc 1734
- tc-1734
- tc-1734
- tc-1734
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07069725 | Phase 1 | May 26, 2025 | AstraZeneca, Clinical Trial Consultants AB, Karolinska Institute |
| NCT06974565 | Phase 1 | May 12, 2025 | AstraZeneca, Parexel |
| NCT06973005 | Phase 1 | May 8, 2025 | AstraZeneca, Parexel |
| NCT06846528 | Phase 1 | Feb 26, 2025 | AstraZeneca, Parexel |
| NCT06812780 | Phase 1 | Feb 4, 2025 | AstraZeneca |
| NCT06750276 | Phase 2 | Dec 6, 2024 | AstraZeneca |
| NCT06138795 | Phase 1 | Nov 20, 2023 | AstraZeneca |
| NCT01466088 | Phase 2 | Oct 1, 2011 | Targacept, University of Arizona |
| NCT00713765 | Phase 1 | Dec 1, 2008 | AstraZeneca, ICON |
| NCT00777361 | Phase 1 | Oct 1, 2008 | AstraZeneca |
| NCT00683462 | Phase 2 | May 1, 2008 | AstraZeneca, Targacept |
| NCT00689559 | Phase 1 | Mar 1, 2008 | AstraZeneca, ICON |
| NCT00686413 | Phase 1 | Jan 1, 2008 | AstraZeneca |
| NCT00686179 | Phase 1 | Jan 1, 2008 | AstraZeneca |
| NCT00692510 | Phase 1 | Nov 1, 2007 | AstraZeneca, ICON |
| NCT00689637 | Phase 1 | Sep 1, 2007 | AstraZeneca, ICON |
| NCT00528905 | Phase 2 | Aug 1, 2007 | AstraZeneca |
| NCT00501111 | Phase 2 | Jul 1, 2007 | AstraZeneca |
| NCT00109564 | Phase 2 | Jan 1, 2005 | Targacept |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 17 | 17 | 2 | 2007 |
| ICON | For profit | 4 | 0 | 1 | 2007 |
| Parexel | For profit | 3 | 0 | 1 | 2025 |
| Targacept | For profit | 3 | 2 | 1 | 2005 |
| Clinical Trial Consultants AB | For profit | 1 | 0 | 1 | 2025 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2011 |
7 organizations
Page 1 / 1